1994
DOI: 10.1101/gad.8.22.2756
|View full text |Cite
|
Sign up to set email alerts
|

Multiple regions of TBP participate in the response to transcriptional activators in vivo.

Abstract: We used mutant yeast and human TBP molecules with an altered DNA-binding specificity to examine the role of TBP in transcriptional activation in vivo. We show that yeast TBP is functionally equivalent to human TBP for response to numerous transcriptional activators in human cells, including those that do not function in yeast. Despite the extensive conservation of TBP, its ability to respond to transcriptional activators in vivo is curiously resistant to clustered sets of alanine substitution mutations in diff… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

6
95
0

Year Published

1995
1995
2001
2001

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 64 publications
(101 citation statements)
references
References 67 publications
6
95
0
Order By: Relevance
“…Since Pol II TAFs are required for activated transcription in vitro in mammalian systems, but not for basal transcription (9,10), this is precisely the phenotype expected for a mutation that interferes with Pol II TAF interactions. Moreover, human TBP with the triple alanine substitution of R231A ϩ R235A ϩ R239A showed reduced in vitro binding to Pol II TAF 250 (36). Consequently, we postulated that the Pol II activation epitope that nearly coincides with our proposed Brf interaction surface is an interaction surface for a Pol II TAF (2), as did Tansey et al (36).…”
Section: Discussionmentioning
confidence: 59%
See 1 more Smart Citation
“…Since Pol II TAFs are required for activated transcription in vitro in mammalian systems, but not for basal transcription (9,10), this is precisely the phenotype expected for a mutation that interferes with Pol II TAF interactions. Moreover, human TBP with the triple alanine substitution of R231A ϩ R235A ϩ R239A showed reduced in vitro binding to Pol II TAF 250 (36). Consequently, we postulated that the Pol II activation epitope that nearly coincides with our proposed Brf interaction surface is an interaction surface for a Pol II TAF (2), as did Tansey et al (36).…”
Section: Discussionmentioning
confidence: 59%
“…Moreover, human TBP with the triple alanine substitution of R231A ϩ R235A ϩ R239A showed reduced in vitro binding to Pol II TAF 250 (36). Consequently, we postulated that the Pol II activation epitope that nearly coincides with our proposed Brf interaction surface is an interaction surface for a Pol II TAF (2), as did Tansey et al (36).…”
Section: Discussionmentioning
confidence: 59%
“…Previous experiments have provided evidence for a specific role of TAF II 250 in vivo, as illustrated by a correlation between transcriptional activation by an altered-specificity TBP mutant and the ability of this mutant to bind TAF II 250 in vitro (56). Evidence for a role of TAF II 250 in transcriptional activation both in vitro and in vivo is also provided by experiments showing that stable expression of TAF II 250 can rescue a temperature-sensitive mutant hamster cell line containing a mutant TAF II 250 (61).…”
Section: Discussionmentioning
confidence: 99%
“…The functional relevance of this interaction was made evident from data showing that missense mutations in Sp1 that disrupt the interaction between TAF II 110 and Sp1 impair the ability of Sp1 to activate transcription (18). Whereas direct interactions between transactivators and Drosophila TAF II 230, or its human homolog TAF II 250, have not been observed, this TAF is essential for activated transcription in vitro (6,56,58,61). It has been speculated that TAF II 230/ TAF II 250 functions as a scaffold protein, binding directly to TBP and recruiting other TAFs to the TFIID complex (6,27,34,36,49,63).…”
mentioning
confidence: 97%
“…PCR fragments corresponding to aa 330 to 518, 238 to 518, and 238 to 572 were ligated into a modified pSBET vector (27) containing a glutathione S-transferase (GST)-coding sequence to generate constructs pSBET-GST-190RbRcRd, pSBET-GST-190RhRaRbRcRd, and pSBET-GST-190RhRaRbRcRdSer, respectively. GST fusion proteins were expressed in Escherichia coli BL21-DE3 (30), and lysates were prepared as described previously (31). Fusion proteins were bound to glutathione-agarose (Sigma), the beads were washed with phosphate-buffered saline containing 0.1% Nonidet P-40 and 10% glycerol, and the bound proteins were eluted with 10 mM glutathione in 50 mM Tris, pH 8.8.…”
Section: Methodsmentioning
confidence: 99%